NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
2.590
-0.350 (-11.90%)
At close: Sep 12, 2025, 4:00 PM EDT
2.650
+0.060 (2.31%)
After-hours: Sep 12, 2025, 8:00 PM EDT
NovaBay Pharmaceuticals Revenue
NovaBay Pharmaceuticals had revenue of $9.78M in the twelve months ending June 30, 2025, up 113.47% year-over-year. In the year 2024, NovaBay Pharmaceuticals had annual revenue of $9.78M, down -6.45%.
Revenue (ttm)
$9.78M
Revenue Growth
+113.47%
P/S Ratio
1.51
Revenue / Employee
$698,643
Employees
14
Market Cap
15.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.78M | -674.00K | -6.45% |
| Dec 31, 2023 | 10.46M | -3.95M | -27.42% |
| Dec 31, 2022 | 14.40M | 4.20M | 41.16% |
| Dec 31, 2021 | 10.20M | 270.00K | 2.72% |
| Dec 31, 2020 | 9.93M | 3.34M | 50.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NBY News
- 17 days ago - NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share - GlobeNewsWire
- 24 days ago - NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - GlobeNewsWire
- 6 months ago - NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire
- 8 months ago - NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal - Business Wire
- 9 months ago - NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders - Business Wire
- 9 months ago - NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting - Business Wire
- 10 months ago - NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 - Business Wire
- 10 months ago - Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand - Business Wire